Class Action Settled
Approximately 25,000 lawsuits were brought in both state and federal court against Bayer and Johnson and Johnson over the manner in which they marketed a popular blood thinner medication known as Xarelto. Xarelto has been approved by the Federal Drug Administration since July of 2011. The class action for these cases recently settled for $775 Million. Simmons and Fletcher, P.C., is no longer taking these cases.
What is Xarelto?
Xarelto is a blood thinner prescribed often to A-Fib patients to prevent blood clots and protect people from strokes. It comes in a pill form that can be ingested on a once-a-day basis. Xarelto is manufactured by Janssen Pharmaceuticals, a division of Johnson and Johnson, and Bayer.
Dangerous Effects of Xarelto
Xarelto thins the blood to reduce the bloods ability to clot. When a person suffers an injury, they need the blood to clot to stop the bleeding. Thus, if the blood thinner’s effects cannot be counteracted, someone on this drug runs a higher risk of bleeding to death if internal bleeding is occurring. Xarelto had no antidote until Andexxa (made by Portola Pharmaceuticals) was approved by the FDA on May 7, 2018.
Xarelto Lawsuits over Marketing Defect Claims
The lawsuits against Xarelto alleged that manufacturers were misleading in the way they marketed the drug. Xarelto was marketed as being more effective at preventing strokes than Coumadin and easier to use (requires less monitoring). However, Coumadin can be counter-acted in the event that someone was in an emergency situation and needed to stop its blood-thinning effects. The Xarelto lawsuits assert that this information should have been disclosed to consumers and medical professional prescribing the drug.
Current Mass Tort Litigation Over Xarelto
Over 25,000 Xarelto lawsuits were filed in State and Federal Courts across the country. Most of those were consolidated in Louisiana under Federal Multi-District Litigation Rules while the remaining lawsuits were consolidated in Philadelphia’s Complex Litigation Center. One Xarelto lawsuit in Philadelphia resulted in a $28 million verdict for the Plaintiff that was later reversed on appeal. Three other cases in federal court resulted in verdicts in favor of the defense. The settlement covers all of the pending lawsuits.
Warning: Never stop taking a prescribed medication without consulting your physician first.
Paul Cannon has practiced personal injury trial law since 1995. He is Board Certified in Personal Injury Trial Law (2005). He has earned recognition as a Super Lawyer by Thompson Reuters in 2017 & 2018, and as a Top 100 Trial Lawyer by the National Trial Lawyers Association in 2017. He is a Shareholder, trial lawyer and online marketing manager at Simmons and Fletcher, P.C. His legal writings have been published by the Texas Bar Journal, Business.com, Lawyer.com HG Legal Resources, Lawfirms.com, and others. He has been asked to give education talks and media interviews on dog bite law.